IMCD (ENXTAM:IMCD) Reports Higher EBITA, Is The Stock Still Cheap?

IMCD (ENXTAM:IMCD) drew fresh attention after reporting a 4% increase in operating EBITA for the first half of 2026 and announcing leadership changes in the US and Brazil.

See our latest analysis for IMCD.

For investors watching IMCD, the recent 1 month share price return of 11.04% and year to date share price return of 25.24% suggest momentum is building, even though the 5 year total shareholder return is down 34.26%.

If you are weighing IMCD’s latest earnings against other opportunities in the market, this can be a good moment to widen your watchlist and uncover 106 top founder-led companies

IMCD now trades at €97.94 while both analyst targets and intrinsic estimates sit higher, leaving a wide gap after the recent rebound. How far is today’s price from what might be considered fair value?

Most Popular Narrative: 16% Undervalued

Compared with IMCD’s last close at €97.94, the most followed narrative fair value of about €116.57 points to a sizeable valuation gap that investors may want to understand more clearly.

IMCD's strategic expansion into high-growth and resilient end-markets (pharma, food & nutrition, personal care) through both organic efforts and targeted M&A increases exposure to industries with strong, recurring demand fundamentals, which can support sustainable revenue and margin expansion as macro uncertainty fades.

Read the complete narrative.

Curious what is baked into that fair value for IMCD? The narrative leans heavily on steady revenue gains, firmer profit margins, and a richer earnings multiple. The mix might surprise you.

Result: Fair Value of €116.57 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the IMCD narrative still faces pressure from currency swings that affect reported margins and from acquisition risks that could weigh on cash generation if integrations disappoint.

Find out about the key risks to this IMCD narrative.

Another View On IMCD’s Valuation

The narrative-based fair value for IMCD points to upside, but the current market multiple tells a different story. At a P/E of 25.1x, IMCD trades above the European Trade Distributors average of 19.1x and the fair ratio of 18.3x. That higher multiple can mean less room for error if growth or margins disappoint.

To understand whether this premium is justified by the latest earnings quality, balance sheet and growth forecasts, it helps to see how the numbers stack up side by side in our valuation breakdown: See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on IMCD leave you unsure, act quickly to review the full picture and consider both sides of the story with 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond IMCD?

If IMCD has your attention, do not stop there. Use this moment to widen your watchlist, deepen your research, and stress test your portfolio ideas.

• Spot potential value opportunities early and compare them with IMCD by checking out 258 high quality undervalued stocks for stocks that may trade below their assessed worth.
• Strengthen your downside protection and focus on resilience by reviewing the 303 resilient stocks with low risk scores that score well on risk metrics and business quality.
• Seek fresh ideas that the market may be overlooking by scanning the screener containing 617 high quality undiscovered gems with strong fundamentals before wider attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com